DFTXDefinium Therapeutics, Inc.
Price
+308%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 10% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for DFTX today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Mixed
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
We are a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. We are developing a pipeline of innovative product candidates targeting neurotransmitter pathways that play key roles in brain health disorders.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 14, 2026On September 14, 2026, the Company posted a presentation discussing the Panorama topline data (the “Presentation”) to its website.Regulation FD disclosure · Form 8-K
- Sep 8, 2026On September 8, 2026, Definium Therapeutics, Inc. (the “Company”) issued a press release (the “Press Release”) announcing that the U.S. Food and Drug Administration has granted breakthrough designation to the Company’s DT120 ODT program for the treatment of major depressive disorder.Other event · Form 8-K
- Aug 12, 2026The information furnished pursuant to this.Regulation FD disclosure · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.